3 ESG Strategy & Goals 3 Health for Humanity 2025 Goals In 2021, we launched our ambitious set of Health for Humanity 2025 Goals that align to our ESG focus areas and foundation of accountability and innovation and show how we hold ourselves publicly accountable in creating a more sustainable society. Through our Health for Humanity Goals, we directly support 11 of the 17 United Nations Sustainable Development Goals (SDGs). ESG Priorities To identify, prioritize and strategically address environmental, social and governance (ESG) topics that can have material impact on society or our business, Johnson & Johnson conducts ESG materiality assessments (Priority Topics Assessments—PTAs) every two to three years or as needed. In 2021, we conducted a PTA with the aim of improving alignment with the evolving needs of stakeholders against an updated list of ESG priority topics. We applied a “double materiality” focus, in which we examined ESG priority topics from two standpoints: the impact of a topic on Johnson & Johnson’s business results and the impact of Johnson & Johnson’s business on people, the environment and society. The highest priority topics were the same as in previous PTAs: consumer health and patient safety; product quality; access; and advancing public health. The insights and data generated from the 2021 PTA informed our ESG strategy. Sustainability Governance The Johnson & Johnson Enterprise Governance Council (EGC) is the primary governance body for ESG topics and implementation of the Company’s Enterprise Risk Management Framework. The EGC is composed of senior leaders who represent our Pharmaceutical, MedTech and Consumer Health business segments and our global Enterprise functions. In 2021, the EGC oversaw our PTA update, ESG strategy development and Health for Humanity 2025 Goals progress, and engaged regularly with teams across the Company on core ESG- driven initiatives such as Our Race to Health Equity. Members of the Executive Committee were engaged in advancing ESG through supporting ESG strategy development, risk management and sponsorship of priority ESG topics. The Board of Directors and its Committees provided oversight on specific ESG topics throughout the year. 2021 Priority Topics Matrix INCREASING IMPORTANCE INCREASING IMPORTANCE External Stakeholder Perspective (Degree of stakeholder concern) Johnson & Johnson Perspective (Impact on business) Environmental impact on human health Consumer health & patient safety Product quality Access Advancing public health Anti-bribery & anti-corruption Bioethics Diversity, equity & inclusion Climate change Human rights R&D & innovation investment Ethics & compliance Workforce safety & well-being Cybersecurity & data privacy Workforce attraction, development & retention Digital innovation Sustainable products & packaging Counterfeit & illicit trade Biodiversity Community economic impact Supplier base transparency & integrity Strengthening health systems Water management Waste management Animal rights & welfare